نتایج جستجو برای: telaprevir

تعداد نتایج: 686  

2014
Eric L. Haseltine Sandra De Meyer Inge Dierynck Doug J. Bartels Anne Ghys Andrew Davis Eileen Z. Zhang Ann M. Tigges Joan Spanks Gaston Picchio Tara L. Kieffer James C. Sullivan

For patients infected with hepatitis C virus (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and ribavirin (RBV) significantly increases the chances of sustained virologic response (SVR) over treatment with Peg-IFN and RBV alone. If patients do not achieve SVR with telaprevir-based treatment, their viral population is often significan...

2014
Marisa Montes Mark Nelson Pierre Marie Girard Joe Sasadeusz Andrzej Horban Beatriz Grinsztejn Natalia Zakharova Antonio Rivero Erkki Lathouwers Katrien Janssen Sivi Ouwerkerk-Mahadevan James Witek

INTRODUCTION We report the SVR12 final analysis of a phase 3 study of telaprevir in combination with peginterferon (P)/ribavirin (R) in HCV-genotype 1, treatment-naïve and -experienced patients with HCV/HIV co-infection (INSIGHT). MATERIALS AND METHODS Patients receiving stable, suppressive HIV antiretroviral (ARV) therapy, containing atazanavir/ritonavir, efavirenz, darunavir/ritonavir, ralt...

2014
Harrys A Torres Ahmed Kaseb Parag Mahale Ethan Miller Catherine Frenette

In patients who undergo liver transplantation (LT), allograft failure secondary to hepatitis C virus (HCV) recurrence after LT accounts for two-thirds of graft failures and deaths. Achievement of sustained virologic response before LT eliminates the risk of HCV recurrence. Only a limited number of studies have evaluated the role of antiviral treatment before LT. No published data are available ...

2017
Kian Bichoupan Neeta Tandon Valerie Martel-Laferriere Neal M Patel David Sachs Michel Ng Emily A Schonfeld Alexis Pappas James Crismale Alicia Stivala Viktoriya Khaitova Donald Gardenier Michael Linderman William Olson Ponni V Perumalswami Thomas D Schiano Joseph A Odin Lawrence U Liu Douglas T Dieterich Andrea D Branch

AIM To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunodeficiency virus-positive patients and patients who received a liver transplant were excluded. Fac...

Journal: :Journal of Microbiology and Infectious Diseases 2015

2013
Adrian Streinu-Cercel Anca Victorița Trifan Florin Alexandru Căruntu Ioan Sporea Liliana Simona Gheorghe Manuela Curescu Mihai Mircea Diculescu Mihai Voiculescu Oliviu Pascu Isabelle Lonjon-Domanec Andrew Martin Hill Sorin Rugină

Methods Patients were treated with telaprevir in combination with peginterferon alfa and ribavirin (PR) for 12 weeks, followed by PR for 12 or 36 weeks. Severe fibrosis/cirrhosis was defined by liver biopsy (Metavir F3-4 or Ishak 3-6) or noninvasive tests. Platelet count >90,000/cmm was required at entry. HCV RNA was evaluated at baseline and Weeks 4 and 12 of treatment. Virological response wa...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید